ArticleJournal of ovarian research2013
First step in developing a 3D biodegradable fibrin scaffold for an artificial ovary.
Article in Journal of ovarian research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Bioengineering trends in female reproduction: a systematic review.Human reproduction update · 2022Pooled it
- New advances in ovarian autotransplantation to restore fertility in cancer patients.Cancer metastasis reviews · 2015Pooled it
- Dynamic in vitro 3D culture of cryopreserved human ovarian tissue: transcriptomic analysis by RNA sequencing.Journal of ovarian research · 2026Article
- Construction and Bioengineering of Human Bioprosthetic Ovaries from Cryopreserved Ovarian Tissue.International journal of molecular sciences · 2025Review
- Three-Dimensionally Printed Agarose Micromold Supports Scaffold-Free Mouse Ex Vivo Follicle Growth, Ovulation, and Luteinization.Bioengineering (Basel, Switzerland) · 2024Article
- Article
- Design and Application Strategies of Natural Polymer Biomaterials in Artificial Ovaries.Annals of biomedical engineering · 2023Review
- Mind the mechanical strength: tailoring a 3D matrix to encapsulate isolated human preantral follicles.Human reproduction open · 2023Article
- Advanced bioengineering of female germ cells to preserve fertility.Biology of reproduction · 2022Review
- An Update on In Vitro Folliculogenesis: A New Technique for Post-Cancer Fertility.Biomedicines · 2022Review
- Biomaterials and advanced technologies for the evaluation and treatment of ovarian aging.Journal of nanobiotechnology · 2022Review
- Female Oncofertility: Current Understandings, Therapeutic Approaches, Controversies, and Future Perspectives.Journal of clinical medicine · 2021Review
- Current and Future Perspectives for Improving Ovarian Tissue Cryopreservation and Transplantation Outcomes for Cancer Patients.Reproductive sciences (Thousand Oaks, Calif.) · 2021Review
- Disease-inducing potential of two leukemic cell lines in a xenografting model.Journal of assisted reproduction and genetics · 2021Article
- Anti-clogging mechanisms of a motion-activated chest tube patency maintenance system: Histology and high-speed camera assessment.Artificial organs · 2020Article
- Advances in the Treatment and Prevention of Chemotherapy-Induced Ovarian Toxicity.International journal of molecular sciences · 2020Review
- Decellularization and recellularization of the ovary for bioengineering applications; studies in the mouse.Reproductive biology and endocrinology : RB&E · 2020Article
- Isolation and characterization of the human ovarian cell population for transplantation into an artificial ovary.Animal reproduction · 2020Article
- Decellularization of the mouse ovary: comparison of different scaffold generation protocols for future ovarian bioengineering.Journal of ovarian research · 2019Article
- Being a good egg in the 21st century.British medical bulletin · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough transplantation of cryopreserved ovarian tissue is a promising approach to restore fertility in cancer patients, it is not advisable for women at risk of ovarian involvement due to the threat of reintroducing malignant cells. The aim of this study was therefore to find an alternative for these patients by development of an artificial ovary.
methodsFor construction of the artificial ovary matrix, we used a central composite design to investigate nine combinations of fibrinogen (mg/ml) and thrombin (IU/mL) (F/T): F1/T4, F12.5/T1, F12.5/T20, F25/T0.1, F25/T4, F25/T500, F50/T1, F50/T20 and F100/T4. From the first qualitative analyses (handling and matrix size), five combinations (F12.5/T1, F25/T4, F50/T20, F50/T1 and F100/T4) yielded positive results. They were further evaluated in order to assess fibrin matrix degradation and homogeneous cell encapsulation (density), survival and proliferation (Ki67), and atresia (TUNEL) before and after 7 days of in vitro culture. To determine the best compromise between maximizing the dynamic density (Y1) and minimizing the apoptosis rate (Y2), we used the desirability function approach.
resultsTwo combinations (F12.5/T1 and F25/T4) showed greater distribution of cells before in vitro culture, reproducible degradation of the fibrin network and adequate support for isolated human ovarian stromal cells, with a high proportion of Ki67-positive cells. SEM analysis revealed a network of fibers with regular pores and healthy stromal cells after in vitro culture with both F/T combinations.
conclusionThis study reports two optimal F/T combinations that allow survival and proliferation of isolated human ovarian cells. Further studies are required to determine if such a scaffold will also be a suitable environment for isolated ovarian follicles.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.